Myriad Women's Health provides the following resources in select languages:

Myriad myRisk® Hereditary Cancer Test enhanced with riskScore®

There's power in knowing

Help your patients get ahead of hereditary cancer.

Why Myriad MyRisk

Myriad myRisk with riskScore blends analysis of genetic risk factors with clinical and cancer family history to deliver the most comprehensive, clinically actionable results to help providers manage their patients’ risk of cancer. This means more of your patients will benefit from valuable information that can make a difference in health outcomes for themselves and for their families.

Reduce false negatives

At Myriad there is not an acceptable false negative rate. We invest heavily in new technologies and techniques to make sure we minimize the potential for error.

Earlier intervention

Identifying cancer at an earlier stage provides you important information to better treat your patients and prevent secondary cancers.

Save time and money

Not only will the testing process be painless, the cost of the test is also painless with Myriad. Myriad strives to keep costs low for patients.

Expect More

riskScore

Clinically validated tool to estimate risk of breast cancer by assessing a combination of genetic markers, clinical factors, and family history

Analytical Validity

Analytically validated high-throughput laboratory with 99.98% accuracy10

Variant Interpretation

Industry leading, FDA-reviewed11 variant interpretation program, as part of the BRACAnalysis CDx PMA, with powerful methods unique to Myriad

Know their risk to protect their future

Approximately 1 in 4 patients in the community OBGYN setting may be at risk for hereditary cancer and meet current screening guidelines for testing.1

    • 90% of high-risk women are not screened for BRCA1/BRCA22
    • Interventions are proven to reduce risk3-6

 

Accurate Results for Actionable Decisions

Myriad is your trusted advisor. Myriad myRisk Hereditary Cancer Test is a multi-gene panel that determines hereditary cancer risk associated with 8 cancer sites:

Breast  | Ovarian  |  Colorectal | Endometrial
Melanoma  | Pancreatic | Gastric | Prostate

Supporting Services with
Myriad CompleteTM

Myriad offers the following through Myriad Complete to help seamlessly integrate testing and screening into your practice.

Education

We provide resources to help you educate your patients about Myriad products.

Access

We offer a comprehensive program to make genetic products accessible for more of your patients.

Results

We deliver screening and testing results effectively and thoroughly so you can focus on care plans.

Consults

We provide consults from genetic counselors tailored to help your patient understand their results.

Together, with Myriad Women's Health

References

  1. DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the CommunityPractice Setting. Obstetrics & Gynecology 2018 – published online before print October 10, 2018.
  2. Bellcross CA, et al. Genet Med. 2015;17(1):43–50.
  3. Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340, 77–84 (1999).
  4. Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616–1622 (2002).
  5. Plevritis, S et al. Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA. 295(20), 2374–2384 (2006).
  6. de Jong, A. E. et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130, 665–671 (2006).
  7. ACOG Committee Opinion: Hereditary Cancer Syndromes and Risk Assessment, No. 634. June 2015, Reaffirmed 2017.
  8. Risk assessment, genetic counseling, and genetic testing for BRCA related cancer in women: U.S. Preventive Services Task Force recommendation statement. JAMA. 2019;322(7):652-665. doi:10.1001/jama.2019.10987 
  9. Reference with permission from NCCN: Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. Version 1.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed June 8, 2020. Available at http://www.nccn.org. 
  10. Judkins T. et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk; BMC Cancer, 2014.
  11. U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH). BRACAnalysis CDxTM approval letter, December 19, 2014. Retrieved November 7, 2018, from http://www.accessdata.fda.gov/cdrh_docs/pdf14/P140020A.pdf.
  12. Mersch J, et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. JAMA – published online September 25, 2018.